Skip to main content

Funding led by D1 Capital Partners and Eventide Asset Management with the participation of additional investors, including returning Series A investors

Product intended to support the continued development of the preclinical pipeline in rare cardiovascular diseases and genetics of Alzheimer’s disease; clinical development of the company’s main programs towards significant data catalysts

NEW YORK, Sep 09, 2021 (GLOBE NEWSWIRE) – LEXEO Therapeutics, a fully integrated, clinical-stage gene therapy company providing adeno-associated virus (AAV) mediated treatments for genetic diseases, announced today hui the closing of a $ 100 million round of B Financing, led by D1 Capital Partners and Eventide Asset Management, and joined by CAM Capital, Verition Fund Management, Laurion Capital Management, Gray’s Creek Capital Partners and existing investors Longitude Capital, Omega Funds, Lundbeckfonden Ventures, PBM Capital, Janus Henderson Investors, Woodline Partners LP, Invus Capital and Alexandria Venture Investments.

Proceeds from the funding will support the development of LEXEO’s expanded pipeline, including newly acquired cardiac gene therapy programs and additional preclinical programs focused on the genetic causes of Alzheimer’s disease (LX1020 and LX1021). The funding will also advance the Company’s three major experimental AAV-mediated gene therapy programs through clinical development to significant inflection points of value: LX2006, an IV-administered gene therapy for cardiomyopathy associated with Friedreich’s ataxia (FA), LX1004, a central nervous system (CNS-administered gene therapy for CLN2 Batten disease and LX1001, a CNS-administered gene therapy for Alzheimer’s disease associated with APOE4.

“As we enter our next phase of growth, we are strongly encouraged by the support of this diverse range of long-term focused investors participating in our Series B funding,” said R. Nolan Townsend, Managing Director of LEXEO Therapeutics. “With this infusion of capital, we plan to advance our pipeline from clinical stages to meaningful short-term data catalysts while establishing leadership positions in the cardiac gene therapy and disease genetics portfolio. Alzheimer’s. “

Dan Sundheim, Founder of D1 Capital Partners, said: “We believe in the mission of LEXEO and are proud to invest in a company led by gene therapy experts. We are impressed with the company’s pipeline and excited to support its continued growth as it strives to develop meaningful treatments for patients.

Joy Ghosh, Senior Research Analyst at Eventide, added, “The LEXEO team applies its expertise and innovative approaches to tackle some of the world’s most devastating genetic diseases. We are confident in their ability to advance various pipeline programs to address both rare monogenic diseases and those affecting larger patient populations, and we look forward to partnering with Nolan and his team on this journey. “

About LEXEO Therapeutics, Inc.

LEXEO Therapeutics is a New York-based fully integrated clinical stage gene therapy company providing disease-modifying treatments for genetic cardiovascular disease and genetic diseases of the central nervous system (CNS). The company aims to apply cutting-edge science to target the underlying causes of rare monogenic diseases and diseases affecting large patient populations. LEXEO’s current pipeline includes adeno-associated virus (AAV) mediated gene therapies in rare heart disease, Batten disease CLN2 and Alzheimer’s disease associated with APOE4. In addition, the company has more than 15 AAV-mediated gene therapy programs in research and development. LEXEO was founded on a well-established legacy of gene therapy research in the Department of Genetic Medicine at Weill Cornell Medicine by a team of pioneering scientists, clinicians and business leaders with deep expertise in gene therapy. For more information, please visit or LinkedIn.

Investor contact
LEXEO Therapeutics, Inc.
[email protected]

Media contact
Sheryl Seapy, the real chemistry
(949) 903-4750
[email protected]

Leave a Reply